Patient Reported Outcomes, Paternity, Relationship, and Fertility in Testicular Cancer Survivors: Results from a Prospective Observational Single Institution Trial
Davide Bimbatti,Eleonora Lai,Francesco Pierantoni,Marco Maruzzo,Aichi Msaki,Chiara De Toni,Michele Dionese,Alessandra Feltrin,Umberto Basso,Vittorina Zagonel
DOI: https://doi.org/10.2147/PPA.S381812
2022-12-24
Patient Preference and Adherence
Abstract:Davide Bimbatti, 1 Eleonora Lai, 1, 2 Francesco Pierantoni, 2, 3 Marco Maruzzo, 1 Aichi Msaki, 1 Chiara De Toni, 1 Michele Dionese, 1, 2 Alessandra Feltrin, 4 Umberto Basso, 1 Vittorina Zagonel 1 1 Oncology 1 Unit, Istituto Oncologico Veneto IOV – IRCCS, Padua, Italy; 2 Department of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy; 3 Oncology 3 Unit, Istituto Oncologico Veneto IOV – IRCCS, Padua, Italy; 4 Hospital Psychology Unit, Istituto Oncologico Veneto IOV – IRCCS, Padua, Italy Correspondence: Davide Bimbatti, Oncology 1 Unit, Istituto Oncologico Veneto, IOV - IRCCS, via Gattamelata 64, Padova, 35128, Italy, Email Purpose: Testicular cancer (TC) is the most common solid tumor in young adults. 95% of patients are cured, but they may experience late adverse effects (anxiety, fear of recurrence, and sexual dysfunction) with an impact on daily life. We attempted to assess Patient Reported Outcomes (PROMs), long-term sexual disorders, and difficulties in achieving fatherhood in a cohort of TC survivors, as well as their possible correlation with previous cancer treatments. Methods: Different questionnaires, such as the Impact of Cancer (IOC) and the Body Image Scale (BIS), were used to investigate the distinct areas of the PROMs. International Index of Erectile Function (IIEF15) and the Premature Ejaculation Diagnostic Tool (PEDT) focused on sexuality and fertility. Patients were prospectively recruited between February 2020 and February 2022. Results: 144 participants completed all the questionnaires. Results showed a good QoL, a moderate fear of TC recurrence, a good satisfaction with their personal body image, low incidence of premature ejaculation and erectile dysfunction. 19.5% of patients who had a testicular implant reported general dissatisfaction. Only 18% of patients had unsuccessfully attempted fatherhood, while the majority had not yet tried, and 23.4% succeeded. A low percentage of patients used procedures assisted reproduction and adoption. Conclusion: This trial supports the use of various questionnaires as a multifactorial tool capable of investigating all the aspects of long-term cancer survivorship. The assessment of medical and psychosocial sequelae is an essential part of patient care and is important for the development of a comprehensive care plan for TC survivors. Keywords: testis cancer, testis cancer survivor, testis cancer PROMs, testis cancer fertility Testicular cancer (TC) is the most common malignancy in young adult, with high cure rate: currently 95% of patients are cure and become cancer survivors. They may experience a wide range of late adverse events: to date there are a few data in literature about the severity of these issues and their impact on daily living, including sexual life and fatherhood. We tried to assess the patient reported outcomes (PROMs), long term sexual issues, difficulties in reaching fatherhood and in general global quality of life of TC survivors. The assessment of the overall burden of medical and psychosocial comorbidities is an essential part of patients' care, and it is important in order to develop comprehensive care plan of TC survivors. Results showed a good QoL, with a moderate fear of TC recurrence, a good satisfaction with personal body image and low rates of premature ejaculation and erectile dysfunction. No significant differences were observed between these outcomes and chemotherapy other therapies received. The majority of the patients did not try to reach fatherhood yet while only few patients tried to reach it without success. These results support the use of various questionnaires as a multifactorial instrument that is able to investigate the most common aspects of long-term cancer survivorship. Testicular cancer (TC) is the most common solid tumor in young men aged between 14 and 40 years, with an estimated 25,000 new cases in Europe each year and a global incidence that has been steadily increasing. 1,2 Therapeutic management consists of radical inguinal orchiectomy, cisplatin-based chemotherapy, radiotherapy, and, in selected cases, surgical resection of distant localizations. The efficacy of these treatments reflects an excellent 5-year survival rate, which is more than 95%. 3 Patients who have been cured face potential short-term and long-term adverse effects. Short-term adverse effects occur during treatment and can be prevented with appropriate hydration, antiemetics, and corticosteroids. 4 The most frequently reported long-term sequelae are cardiovascular diseases, peripheral neuropathy, second malignancies, hypogonadism, -Abstract Truncated-
medicine, general & internal